AstraZeneca PLC Release: Results From Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013

Published: May 21, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ORLANDO, Fla.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week (DDW) meeting in Orlando, Florida. Naloxegol is a peripherally-acting mu-opioid receptor antagonist, which has been specifically designed for the treatment of opioid-induced constipation (OIC), a common and often debilitating side effect of prescription opioid pain medicines.

Help employers find you! Check out all the jobs and post your resume.

Back to news